54757-17-4

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule of the compound.

Explanation

The compound is derived from benzene by substituting a chloromethyl group at the 1st position and adding methoxy groups at the 2nd and 5th positions, as well as methyl groups at the 3rd, 4th, and 6th positions.

Explanation

The compound is used as a building block or reagent in the production of various pharmaceuticals and other chemicals.

Explanation

It serves as a reagent in organic chemistry, aiding in the formation of new compounds through chemical reactions.

Explanation

The compound can be used as a starting material to create a variety of other organic compounds through chemical reactions.

Explanation

The compound has the potential to cause irritation upon contact with skin or eyes, necessitating proper handling and safety precautions.

Explanation

Direct contact with the compound can result in skin and eye irritation, emphasizing the importance of using appropriate protective equipment when handling it.

Chemical structure

Chloromethyl derivative of 2,5-dimethoxy-3,4,6-trimethyl-benzene

Application

Synthesis of pharmaceuticals and in the chemical industry

Application

Reagent in organic chemistry

Application

Building block for the synthesis of other organic compounds

Safety

Potential irritant

Safety

Skin and eye irritation

Upstream product

• 50-00-0 formaldehyd 
• 4537-09-1 1,4-dimethoxy-2,3,5-trimethyl-benzene 
• 700-13-0 Trimethylhydroquinone 
• 103808-42-0 2,5-dimethoxy-3,4,6-trimethylbenzaldehyde 
• 117574-74-0 (2,5-dimethoxy-3,4,6-trimethylphenyl)methanol 

Downstream Products

• 144707-05-1 1,4-dimethoxy-2-methoxymethyl-3,5,6-trimethylbenzene 
• 144707-04-0 dimethyl esther of 2-(2,5-dimethoxy-3,4,6-trimethylphenylmethyl)malonic acid 
• 117574-74-0 (2,5-dimethoxy-3,4,6-trimethylphenyl)methanol 
• 109885-41-8 5-(chloromethyl)-2,3,5-trimethylcyclohexa-2,5-diene-1,4-dione 
• 66958-66-5 trans-2,3,5-trimethyl-6-(3',7',11',15'-tetramethyl-2',6',10',14'-hexadecatetraenyl)-1,4-benzoquinone 
• 134824-31-0 2,3,6-Trimethyl-5-farnesyl-1,4-benzoquinone 
• 53711-21-0 2,5-dihydroxy-3,4,6-trimethyl-benzaldehyde 
• 500886-73-7 (2,5-dimethoxy-3,4,6-trimethyl-phenyl)-acetic acid 
• 1026187-07-4 1-hexyl-2,5-dimethoxy-3,4,6-trimethyl-benzene 
• 1026742-88-0 1-octyl-2,5-dimethoxy-3,4,6-trimethyl-benzene 
• 1010114-85-8 C₁₉H₂₀N₂O₈ 
• 1010114-70-1 C₁₉H₂₁NO₆ 
• 1010114-63-2 2,5-dimethoxy-3,4,6-trimethylbenzyl 4-nitrobenzoate 
• 1010114-81-4 C₁₉H₂₂O₄ 

Relevant academic research and scientific papers

New Drug Delivery System for Crossing the Blood Brain Barrier

New ubiquinol analogs are disclosed, as well as methods of using these compounds to deliver drug moieties to the body.

Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed,

Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed,

Radical reactions leading to substituted coumarins

The reaction of 4-hydroxycoumarins with a series of quinonic chlorides under photostimulation was shown to provide an efficient approach to 3- alkylated coumarin derivatives. Alkylation reactions of this type proceeded via an electron transfer mechanism (

Diels-alder trapping of ortho-quinone methides. A new entry to substituted xanthene- 1,4-diones

Highly regioselective Diels-Alder reactions of a non-protected β-hydroxy quinone have been achieved after formation of chelated lithium alkoxides. In this report, we demonstrate on a model system, that the selectivity of reactions based on 1,3-dioxy-subst

An expeditious route to CoQ(n), Vitamins K1 and K2, and related allylated para-quinones utilizing Ni(0) catalysis

Coupling reactions between vynylalanes and chloromethylated para-quinones, mediated by catalytic amounts of Ni(0), lead directly to allylated products, including coenzyme Q, and vitamins K1 and K2.

SYNTHESIS OF DIQUINONE DERIVATIVES OF DEUTEROPORPHYRIN IX FOR THE STUDY OF THE FIRST STAGE IN THE PROCESS OF PHOTOSYNTHESIS

Diquinone derivatives of deuteroporphyrin IX containing covalent bridges of different lengths between the chromophores have been synthesized.The compounds were prepared by the condensation of hydroxy-quinones with deuteroporphyrin IX using a mixed anhydri

S(RN)1 reactions of a tetrasubstituted-1,4-benzoquinone

The C-alkylation reaction of 2-chloromethyl-3,5,6-trimethyl-1,4-benzoquinone by 2-nitropropane anion is shown to proceed by the S(RN)1 mechanism. This mechanism is confirmed by the inhibitory effects of dioxygen, p-dinitrobenzene, cupric chloride and di-t

Dual Inhibitors of Thromboxane A2 Synthase and 5-Lipoxygenase with Scavenging Activity of Active Oxygen Species. Synthesis of a Novel Series of (3-Pyridylmethyl)benzoquinone Derivatives

A novel series of (3-pyridylmethyl)benzoquinone derivatives was molecular designed and synthesized for the dual purpose of inhibiting thromboxane A2 and leukotriene biosynthesis enzymes and scavenging active oxygen species (AOS).They were evaluated for inhibition of TXA2 synthase, inhibition of 5-lipoxygenase, and for their scavenging activity of AOS using the thiobarbituric acid method. 2,3,5-Trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone (24, CV-6504) was the most promising derivative since it showed efficient AOS scavenging activity (inhibition of lipid peroxidation in rat brain homogenates: IC50 = 1.8 10-6 M) as well as potent, specific, and well-balanced inhibitory effects on both enzymes (inhibitory effect on TXA2 synthase in human blood, IC50 = 3.3 10-7 M; inhibitory effect on 5-lipoxygenase in human blood, IC50 = 3.6 10-7 M).In adriamycin-induced proteinuria in a rat model, compound 24 at 10 mg/kg per day (po) suppressed proteinuria by more than 50percent.The proteinuria, however, could not be reduced by single administration of an inhibitor specific for thromboxane A2 synthase or for 5-lipoxygenase .The proteinuria was also not reduced by administration of an AOS scavenger, 2-O-octadecylascorbic acid (4, CV-3611).Triple function compounds such as compound 24 that specifically inhibit both enzymes as well as scavenge AOS possess a variety of pharmacologically beneficial effects.